A therapeutic preparation of polyclonal human IgG, i.e. , intravenous immunoglobulin (IVIg), has been employed to treat several inflammatory and autoimmune disorders. B cells are supposed to be a target of IVIg, but the molecular mechanism is elusive because of the lack of a suitable experimental system. To gain an insight into the beneficial effect of IVIg on B cells, we first established an experimental setting in which IVIg modulates a murine B cell function in vitro , and then aimed at identifying the mechanistic features at the molecular level. Here we show that IVIg down-regulates IL-10 production by CpG-activated B cells in vitro . The responsible component of IVIg was identified as the F(ab’) 2 portion, whose polyclonality is mandatory for the suppressive effect. IVIg, bound to the surface of activated B cells, was found to be co-localized with intracellular SHP-1 on confocal laser microscopy, suggesting that B cell-surface immunoreceptor tyrosine-based inhibitory motif-harboring receptors that recruit SHP-1 are target molecules for IVIg in our experimental setting. Overall, we postulate a scenario in which IVIg attenuates B cells by suppressing IL-10 production, a B cell growth factor, and thus down-regulates the production of pathogenic antibodies.
Ballow, M. (2011) The IgG molecule as a biological immune response modifier: mechanisms of action of intravenous immune serum globulin in autoimmune and inflammatory disorders. Journal of Allergy and Clinical Immunology, 127, 315-323. doi:10.1016/j.jaci.2010.10.030
Anthony, R.M., Wermeling, F. and Ravetch, J.V. (2012) Novel roles for the IgG Fc glycan. Annals of the New York Academy of Sciences, 1253, 170-180. doi:10.1111/j.1749-6632.2011.06305.x
Ibá?ez, C. and Montoro-Ronsano, J.B. (2003) Intravenous immunoglobulin preparations and autoimmune disorders: Mechanisms of action. Current Pharmaceutical Biotechnology, 4, 239-247. doi:10.2174/1389201033489775
Lemieux, R., Bazin, R. and Néron, S. (2005) Therapuetic intravenous immunoglobulins. Molecular Immunology, 42, 839-848.doi:10.1016/j.molimm.2004.07.046
Hartung, H.P. (2008) Advances in the understanding of the mechanism of action of IVIg. Journal of Neurology, 255, 3-6. doi:10.1007/s00415-008-3002-0
Néron, S., Boire, G., Dussault, N., Racine, C., de Brum-Fernandes, A.J., C?té, S. and Jacques, A. (2009) CD40-activated B cells from patients with systemic lupus erythematosus can be modulated by therapeutic immunoglobulins in vitro. Archivum Immunologiae et Therapiae Experimentalis, 57, 447-458. doi:10.1007/s00005-009-0048-3
Branch, D.W., Porter, T.F., Paidas, M.J., Belfort, M.A. and Gonik, B. (2001) Obstetric uses of intravenous immunoglobulin: Successes, failures, and promises. Journal of Allergy and Clinical Immunology, 108, S133-S138. doi:10.1067/mai.2001.117821
Kaveri, S.V., Dietrich, G., Hurez, V. and Kazatchkine, M.D. (1992) Intravenous immunoglobulins (IVIg) in the treatment of autoimmune diseases. Clinical and Experimental Immunology, 86, 192-198. doi:10.1111/j.1365-2249.1991.tb05794.x
Ehrenstein, M.R. and Notley, C.A. (2010) The importance of natural IgM: Scavenger, protector and regulator. Nature Reviews Immunology, 10, 778-786. doi:10.1038/nri2849
Griffin, D.O. and Rothstein, T.L. (2012) Human b1 cell frequency: Isolation and analysis of human b1 cells. Frontiers in Immunology, 3, 122. doi:10.3389/fimmu.2012.00122
Nimmerjahn, F. and Ravetch, J.V. (2006) Fc receptors: Old friends and new family members. Immunity, 24, 19-28. doi:10.1016/j.immuni.2005.11.010
Takai, T., Ono, M., Hikida, M., Ohmori, H. and Ravetch, J.V. (1996) Augmented humoral and anaphylactic responses in Fc RII-deficient mice. Nature, 379, 346-349. doi:10.1038/379346a0
Jellusova, J. and Nitschke, L. (2011) Regulation of B cell functions by the sialic acid-binding receptors Siglec-G and CD22. Frontiers in Immunology, 2, 96. doi:10.3389/fimmu.2011.00096
Hayami, K., Fukuta, D., Nishikawa, Y., Yamashita, Y., Inui, M., Ohyama, Y., Hikida, M., Ohmori, H. and Takai, T. (1997) Molecular cloning of a novel murine cell-surface glycoprotein homologous to killer cell inhibitory receptors. The Journal of Biological Chemistry, 272, 7320-7327. doi:10.1074/jbc.272.11.7320
Kubagawa, H., Burrows, P.D. and Cooper, M.D. (1997) A novel pair of immunoglobulin-like receptors expressed by B cells and myeloid cells. Proceedings of the National Academy of Sciences of the United States of America, 94, 5261-5266. doi:10.1073/pnas.94.10.5261
Ujike, A., Takeda, K., Nakamura, A., Ebihara, S., Akiyama, K. and Takai, T. (2002) Impaired dendritic cell maturation and increased TH2 responses in PIR-B-/-mice. Nature Immunology, 3, 542-548. doi:10.1038/ni801
Nitschke, L., Carsetti, R., Ocker, B., K?hler, G. and Lamers, M.C. (1997) CD22 is a negative regulator of B-cell receptor signalling. Current Biology, 7, 133-143. doi:10.1016/S0960-9822(06)00057-1
Parr, D., Connell, G., Kells, D. and Hofmann, T. (1976) Fb’2, a new peptic fragment of human immunoglobulin G. Biochemical Journal, 155, 31-36.
Snigurowicz, J. and Powiertowska, M.R. (1980) Papain hydrolysis products in four M-IgG subclass. Archivum Immunologiae, 28, 265-273.
Virella, G. and Parkhouse, R. (1971) Papain sensitivity of heavy chain sub-classes in normal human IgG and localization of antigenic determinants for the sub-classes. Immunochemistry, 8, 243-250. doi:10.1016/0019-2791(71)90478-2
Kubo, T., Uchida, Y., Watanabe, Y., Abe, M., Nakamura, A., Ono, M., Akira, S. and Takai, T. (2009) Augmented TLR9-induced Btk activation in PIR-B-deficient B-1 cells provokes excessive autoantibody production and autoimmunity. The Journal of Experimental Medicine, 206, 1971-1982.doi:10.1084/jem.20082392
Parnes, J.R. and Pan, C. (2000) CD72, a negative regulator of B-cell responsiveness. Immunological Reviews, 176, 75-85.doi:10.1034/j.1600-065X.2000.00608.x
Li, D.H., Winslow, M.M., Cao, T.M., Chen, A.H., Davis, C.R., Mellins, E.D., Utz, P.J., Crabtree, G.R. and Parnes, J.R. (2008) Modulation of peripheral B cell tolerance by CD72 in a murine model. Arthritis and Rheumatism, 58, 3192-3204.doi:10.1002/art.23812
Hoffmann, A., Kerr, S., Jellusova, J., Zhang, J., Weisel, F., Wellmann, U., Winkler, T.H., Kneitz, B., Crocker, P.R. and Nitschke, L. (2007) Siglec-G is a B1 cell-inhibitory receptor that controls expansion and calcium signaling of the B1 cell population. Nature Immunology, 8, 695-704. doi:10.1038/ni1480
Ono, M., Bolland, S., Tempst, P. and Ravetch, J.V. (1996) Role of the inositol phosphatase SHIP in negative regulation of the immune system by the receptor Fc RIIB. Nature, 383, 263-266.doi:10.1038/383263a0
Leucht, S., Uttenreuther-Fischer, M.M., Gaedicke, G. and Fischer, P. (2001) The B cell superantigen-like interaction of intravenous immunoglobulin (IVIG) with Fab fragments of V(H) 3-23 and 3-30/3-30.5 germline gene origin cloned from a patient with Kawasaki disease is enhanced after IVIG therapy. Clinical Immunology, 99, 18-29. doi:10.1006/clim.2001.5004
Proulx, D.P., Aubin, E., Lemieux, R. and Bazin, R. (2009) Spontaneous internalization of IVIg in activated B cells. Immunology Letters, 124, 18-26. doi:10.1016/j.imlet.2009.03.012
Sé?té, J.F., Cornec, D., Renaudineau, Y., Youinou, P., Mageed, R.A. and Hillion, S. (2010) IVIg modulates BCR signaling through CD22 and promotes apoptosis in mature human B lymphocytes. Blood, 116, 1698-1704. doi:10.1182/blood-2009-12-261461
Séité, J.F., Guerrier, T., Cornec, D., Jamin, C., Youinou, P. and Hillion, S. (2011) TLR9 responses of B cells are repressed by intravenous immunoglobulin through the recruitment of phosphatase. Journal of Autoimmunity, 37, 190-197.doi:10.1016/j.jaut.2011.05.014
Saraiva, M. and O’Garra, A. (2010) The regulation of IL-10 production by immune cells. Nature Reviews Immunology, 10, 170-181.doi:10.1038/nri2711
O’Garra, A., Barret, F.J., Castro, A.G., Vicari, A. and Hawrylowicz, C. (2008) Strategies for use of IL-10 or its antagonists in human disease. Immunological Reviews, 223, 114-131.doi:10.1111/j.1600-065X.2008.00635.x
Kessel, A., Peri, R., Haj, T., Snir, A., Slobodin, G., Sabo, E., Rosner, I., Shoenfeld, Y. and Toubi, E. (2011) IVIg attenuates TLR-9 activation in B cells from SLE patients. Journal of Clinical Immunology, 31, 30-38. doi:10.1007/s10875-010-9469-3